Skip to main content
OPKO Health Inc. logo

OPKO Health Inc. — Investor Relations & Filings

Ticker · OPK ISIN · US68375N1037 LEI · 529900A4S2D4OGOJLL02 TA Human health and social work activities
Open in API
Filings indexed 3,780 across all filing types
Latest filing 2025-01-10 Report Publication Anno…
Country US United States of America
Listing TA OPK

About OPKO Health Inc.

https://www.opko.com

OPKO Health, Inc. is a fully-integrated healthcare company operating in both pharmaceuticals and diagnostics. Its pharmaceutical division develops and commercializes novel therapies for serious diseases. Key marketed products include NGENLA™, a long-acting treatment for pediatric growth hormone deficiency partnered with Pfizer, and RAYALDEE®. The company's research focuses on advancing multispecific therapies for cancers and infectious diseases. Through its subsidiary, BioReference Laboratories, OPKO operates one of the largest full-service clinical reference laboratories in the U.S., providing comprehensive diagnostic testing services to millions of patients annually.

Recent filings

Filing Released Lang Actions
To Present at the 43rd Annual J.P. Morgan Healthcare Conference
Report Publication Announcement Classification · 98% confidence The document is very short (1859 chars) and explicitly states: "Attached hereto is a report on*OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference* *20250110PR_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report or event material, rather than the full content of that material. The content relates to a presentation at a major conference (J.P. Morgan Healthcare Conference), which often falls under Investor Presentations (IP) or general regulatory announcements. Since this document is merely announcing the availability of the presentation material (implied by the PDF attachment reference), it fits the 'Menu vs Meal' rule best as a Report Publication Announcement (RPA). It is not a full Investor Presentation (IP) itself, but the notice of its release.
2025-01-10 English
OPKO Health’s ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck
Regulatory Filings Classification · 100% confidence The document is a press release announcing a significant operational event: the dosing of the first participant in a Phase I clinical study for an Epstein-Barr virus (EBV) vaccine candidate developed by ModeX Therapeutics (an OPKO Health company) in collaboration with Merck. It details the scientific background, the nature of the collaboration, and includes standard cautionary language typical of corporate news releases. This type of announcement, focusing on clinical trial progress and partnership milestones, is best classified as an Earnings Release (ER) if it were quarterly results, but since it is a specific operational update that doesn't fit the other categories perfectly (it's not a full financial report, management change, or dividend notice), it falls under the general category for corporate news announcements. Given the options, 'Earnings Release' (ER) is often used broadly for initial results/updates, but 'Regulatory Filings' (RNS) is the best fit for a general press release announcing clinical progress that doesn't match a more specific category like MANG, DIV, or CAP. However, since this is a major operational update announcing the start of human trials and triggering a milestone payment, it is a key piece of news. In many financial databases, press releases announcing clinical trial milestones are often categorized under 'Earnings Release' (ER) if they are the primary source of news for that period, or sometimes as 'Regulatory Filings' (RNS) if they are purely informational. Given the structure and content (headline announcement, key bullet points, executive quotes), it strongly resembles an Earnings Release format, even though it's not reporting revenue/profit. Since it's a major, time-sensitive announcement of progress, ER is a strong candidate, but RNS is the designated fallback for general regulatory/corporate announcements. Let's re-evaluate: It is not a formal regulatory filing like a 10-K or DEF 14A. It is a press release. If it were a summary of quarterly results, it would be ER. Since it's a specific operational milestone announcement, RNS (Regulatory Filings/General Announcement) is the most appropriate catch-all for non-standard, yet important, corporate news releases that don't fit the other specific codes.
2025-01-07 English
OPKO Health’s ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck
Report Publication Announcement Classification · 98% confidence The document is very short (1863 characters) and explicitly states, "Attached hereto is a report on*���� ��� ����� ������ �� ����� ������ ����� ������ ������ ��� ���� �������-��* *20250107PR_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report, rather than the full report content. It is filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE) under 'Immediate Report Regulation 4 of the Securities Regulations...'. Since it is an announcement of a report publication and does not fit neatly into specific categories like ER, IR, or 10-K, the most appropriate classification based on Rule 2 (Menu vs Meal) and the available definitions is Report Publication Announcement (RPA).
2025-01-07 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIE-Phillip Frost, M.D., ET AL
Director's Dealing Classification · 100% confidence The document text contains the header 'UNITED STATES SECURITIES AND EXCHANGE COMMISSION' and explicitly mentions 'Form 4 or Form 5 obligations' and 'Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934'. Form 4 is the standard SEC filing used to report changes in beneficial ownership of securities by company insiders (directors, officers, or 10% owners). This directly corresponds to the definition of Director's Dealing (DIRS).
2024-12-15 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIE-Phillip Frost, M.D., ET AL
Regulatory Filings Classification · 95% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). The title explicitly mentions 'interested party transaction' and the body states, 'Attached hereto is a report on *interested party transaction* *20241215Form4_isa.pdf*'. Since the document itself is short and serves primarily to announce the publication of an attached report concerning a specific transaction (which often falls under insider/related party disclosures), it fits the criteria for a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the specific nature of the content (related party transaction disclosure), and the fact that it is an announcement referencing an attached PDF, RPA is a strong candidate, but since 'interested party transaction' is not explicitly covered by a unique code other than general regulatory filings, and it is an immediate report, RNS (Regulatory Filings) is the most appropriate fallback for a specific, non-standard disclosure announcement that isn't a core financial report (10-K, IR, ER). However, looking closely at the definitions, 'interested party transaction' is a specific type of disclosure. Since there is no specific code for 'Interested Party Transaction', and it is an announcement of a report, RPA is plausible. But RNS is the general catch-all for regulatory announcements. Given the context of ISA/TASE filings, RNS is the safest general regulatory classification when a specific code is missing. The document is very short and announces an attached report, suggesting RPA or RNS. I will classify it as RNS as it is a mandatory regulatory filing announcement that doesn't fit the other specific categories.
2024-12-15 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES -Phillip Frost, M.D., ET AL
Director's Dealing Classification · 100% confidence The document text explicitly contains the header "FORM 4" and references sections of the Securities Exchange Act of 1934, specifically mentioning "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES" and instructions related to Section 16. Form 4 is the standard SEC filing used by corporate insiders (directors, officers, or 10% owners) to report changes in their beneficial ownership of the company's securities. This directly corresponds to the definition of Director's Dealing (DIRS).
2024-12-12 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.